Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOral - PhysicianPharm

11C-MC1 has adequate sensitivity to measure low density cyclooxygenase 2 (COX-2) in healthy human brain

Xuefeng Yan, Andrea Zhang, Sami Zoghbi, Jeih-San Liow, Cheryl Morse, Maria Ferraris Araneta, Lester Manly, Maia Van Buskirk, Bruny Kenou, Sara Rubovits, William Miller, Victor Pike, Paolo Zanotti Fregonara and Robert Innis
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 103;
Xuefeng Yan
1Molecular Imaging Branch National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Zhang
1Molecular Imaging Branch National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sami Zoghbi
1Molecular Imaging Branch National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeih-San Liow
1Molecular Imaging Branch National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheryl Morse
1Molecular Imaging Branch National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Ferraris Araneta
1Molecular Imaging Branch National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lester Manly
1Molecular Imaging Branch National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maia Van Buskirk
1Molecular Imaging Branch National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruny Kenou
1Molecular Imaging Branch National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Rubovits
1Molecular Imaging Branch National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Miller
1Molecular Imaging Branch National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor Pike
1Molecular Imaging Branch National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Zanotti Fregonara
1Molecular Imaging Branch National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Innis
1Molecular Imaging Branch National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

103

Introduction: Cyclooxygenase enzymes (COX) are important targets for neuroinflammation. COX-1 is constitutively present at such high density in the brain and periphery that it can measured with PET imaging using a COX-1 selective radioligand (doi: 10.1021/acschemneuro.8b00103). In contrast, COX-2 is present at low density in healthy tissue but can be markedly upregulated by inflammation. 11C-MC1 is a selective and potent radioligand for COX-2, and it detected COX-2 in nonhuman primates after intracerebral injection of an inflammogen. We have found that in patients with rheumatoid arthritis, 11C-MC1 detected upregulated COX-2 in symptomatic joints (doi: 10.1186/s12974-020-01804-6). The purpose of this study was to determine if 11C-MC1 could measure COX-2 in healthy human brain.

Methods: Five healthy participants were injected with 11C-MC1 (730 ± 37 MBq) and had two brain PET scans for 120 minutes with concurrent arterial sampling. The baseline scan was followed by one after blockade with celecoxib (600 mg p.o.), a preferential COX-2 inhibitor. Binding to the enzyme was calculated as total distribution volume corrected for free parent fraction in plasma (VT/fp) using a two-tissue compartment model (2TCM), and the receptor occupancy was determined using the Lassen plot.

Results: After injection of 11C-MC1, the concentration of brain radioactivity peaked at 4.0 SUV at ~2.8 minutes and declined to 16% of the peak at 120 minutes. The brain time-activity curve was reasonably well-fitted to a 2TCM and provided stable values of VT after 40 minutes (i.e. within 10% of terminal values at 120 min). However, the measured values of VT after 60 minutes were higher than the fitted values, which might reflect accumulation of small amount of radiometabolites in brain. Nondisplaceable uptake (VND), calculated from the Lassen plot, was 80-90% of total uptake, and specific uptake (VS) was only 10-20% of VT. Based on the Lassen plot, celecoxib occupied 86% of available COX-2 in the brain. The regions with the highest amount of specific binding were occipital cortex, insula, and prefrontal cortex. Regional brain distribution of specific binding correlated with that of regional mRNA transcripts of the COX-2 gene obtained from the Allen Brain Atlas.

Conclusions: The uptake of 11C-MC1 in healthy human brain reflects specific binding to COX-2 based on blockade by celecoxib and by the PET distribution of the enzyme correlating with the density of the gene transcript. Based on these preliminary results, 11C-MC1 has adequate sensitivity to measure the low-density of COX-2 in a healthy human brain. However, the specific binding was only 10-20% of total uptake, and greater confidence in these results will likely require studying neuroinflammatory disorders with higher density of COX-2. Acknowledgments: Intramural Research Program at the National Institute of Mental Health

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
11C-MC1 has adequate sensitivity to measure low density cyclooxygenase 2 (COX-2) in healthy human brain
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
11C-MC1 has adequate sensitivity to measure low density cyclooxygenase 2 (COX-2) in healthy human brain
Xuefeng Yan, Andrea Zhang, Sami Zoghbi, Jeih-San Liow, Cheryl Morse, Maria Ferraris Araneta, Lester Manly, Maia Van Buskirk, Bruny Kenou, Sara Rubovits, William Miller, Victor Pike, Paolo Zanotti Fregonara, Robert Innis
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 103;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
11C-MC1 has adequate sensitivity to measure low density cyclooxygenase 2 (COX-2) in healthy human brain
Xuefeng Yan, Andrea Zhang, Sami Zoghbi, Jeih-San Liow, Cheryl Morse, Maria Ferraris Araneta, Lester Manly, Maia Van Buskirk, Bruny Kenou, Sara Rubovits, William Miller, Victor Pike, Paolo Zanotti Fregonara, Robert Innis
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 103;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • Cyclooxygenases as Potential PET Imaging Biomarkers to Explore Neuroinflammation in Dementia
  • Google Scholar

More in this TOC Section

Oral - PhysicianPharm

  • Safety and efficacy of radioligand therapy with 177lutetium-PSMA-617 within 3 months after 223Radium-dichloride
  • Usefulness of99mTc SESTAMIBI Scintigraphy in Persistent Hyperparathyroidism after Kidney Transplant
  • Toll-like receptor 5 in triple-negative breast cancer: a novel reporter for tumor progression
Show more Oral - PhysicianPharm

Advances in Clinical Neuroimaging

  • 18F-MK6240 longitudinal tau PET in ageing and Alzheimer's disease
  • Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma
  • Neuroinflammation in Semantic Variant Primary Progressive Aphasia
Show more Advances in Clinical Neuroimaging

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire